Close menu




NOVAVAX INC. DL-_01

Photo credits: pixabay.com

Commented by Mario Hose on January 20th, 2022 | 11:08 CET

Cardiol, Novavax, Valneva - Why it's worth buying now!

  • Investments

The trading week is coming to an end and on Thursday the German benchmark index DAX continues to trade below the psychological mark of 16,000 points at a level of 15,785 points and an increase of 0.10%. The rest of today and Friday remain to make a jump. It will probably depend on the guidance from the U.S., but at the hour, U.S. futures are all green. MDAX last traded at 34,135 points (+0.07%), TecDAX at 3,544 points (+0.07%) and SDAX at 15,626 points up 0.33%. Companies from the biotech sector are again in the focus of the investors today.

Read

Commented by Armin Schulz on January 19th, 2022 | 13:14 CET

Novavax, Meta Materials, BASF - Innovations offer great return opportunities

  • Technology

Companies that provide innovations to solve existing problems are ideal investment targets. Filtering out suitable candidates is the most critical task for an investor. Some products require little explanation. For companies developing advanced technologies, patents can give an indication of the Company's future prospects. In any case, the market that the products can serve should be analyzed. Today, we look at three innovative companies.

Read

Commented by Carsten Mainitz on January 18th, 2022 | 13:07 CET

Ayurcann, Novavax, Covestro - The stragglers are coming!

  • Cannabis

Humanity continues to find itself in the clutches of the Corona pandemic, the infection figures are rising, and the demand from politicians for mandatory vaccination is becoming louder and louder. While BioNTech and Pfizer vaccines and Moderna have dominated to date, new vaccine manufacturers are entering the market in the next wave. The situation is similar in the cannabis industry. After a boom about 3 years ago, the market leaders have since lost up to 80% of their value. Legalization and the rise of Cannabis 3.0. will pave the way for new companies.

Read

Commented by Mario Hose on January 14th, 2022 | 12:17 CET

Natural active ingredient against Covid-19: BioNTech, Cardiol, Novavax, Valneva in focus

  • Covid-19

At the end of the week, trading on the German stock exchanges has been rather slow so far. The German leading index DAX is quoted at a level of 15,922 points and thus around 0.01% up. The index of the second tier, MDAX, traded last at 34,626 points (-0.11%), TecDAX at 3,537 points (-0.67%) and SDAX at 15,904 points with 0.43% in the red. A study from the U.S. will influence the future development of vaccine manufacturers in connection with Covid-19, according to initial research.

Read

Commented by André Will-Laudien on January 12th, 2022 | 11:03 CET

Valneva, Cardiol Therapeutics, Novavax: Hitting the nail on the head!

  • Biotechnology

What is the correlation between the development of drugs or vaccines and the price of the company in question on the stock market? Difficult to answer because there is an almost infinite number of research areas in the field of biotechnology. Not all of them are at the center of media interest, while some topics, in contrast, experience true hype phases. COVID-19 is a viral disease that is to be overcome with all available research resources, and the attention on the capital markets is correspondingly high. Those who can demonstrate success in this area achieve high prices and valuations. But who will deliver the ultimate vaccine or a revolutionary drug to treat infected people? Lots of speculation, risks and opportunities in equal measure. We take a look at some interesting companies.

Read

Commented by Carsten Mainitz on December 28th, 2021 | 11:26 CET

Novavax, XPhyto Therapeutics, Bayer - Corona shares for 2022!

  • Biotechnology

The head of the Robert Koch Institute, Lothar Wieler, warned a few days ago that the healthcare system would be overburdened and critical care structures impaired if the feared Omicron wave could not be curbed. This situation illustrates that the pandemic is far from letting us go. Vaccine manufacturers and pharmaceutical companies will continue to benefit. Their shares should also be on the winning side next year.

Read

Commented by Stefan Feulner on December 23rd, 2021 | 11:15 CET

Novavax, Sativa Wellness Group, Bayer - The next wave ignites

  • Cannabis

There is great concern in society due to the Omicron variant. Reason enough for politicians to further tighten measures, even for the approximately 70% of fully vaccinated people in the Federal Republic. The federal and state governments decided on stricter contact restrictions, large events without spectators and a new vaccination target. By the end of January, a further 30 million booster, first and second vaccinations are to be achieved. As a result, vaccine manufacturers are experiencing another boom. Meanwhile, a new vaccine is coming to Germany to change the minds of vaccination skeptics.

Read

Commented by Nico Popp on December 22nd, 2021 | 13:50 CET

BioNTech, Novavax, Cardiol Therapeutics: This pandemic profiteer is as cheap as can be

  • Biotechnology

Omicron is coming; that much seems certain. But what does the virus mean for the stock market? Currently, the forecasts of the modelers are dominating the news. While some see it as scaremongering, others consider epidemiological models a rational approximation of what we face. Like a crystal ball, so to speak, but without the hocus-pocus. To assess the situation as an investor, it makes sense to assume neither the best nor the worst. We analyze the current viral situation and explain what this could mean for typical Corona stocks.

Read

Commented by Fabian Lorenz on December 8th, 2021 | 14:02 CET

Valneva, Novavax, Manganese X Energy: The new pandemic fighters?

  • Covid-19

In the fight against the fourth wave of Corona, German industry is now also becoming active. In support of the vaccination campaign, numerous well-known corporations are changing their advertising slogans. Since November 7, more than 150 companies - including BMW, McDonald's, Edeka, Sparkassen, and Volksbanken - have been jointly promoting the corona vaccination. The campaign was developed by the Berlin advertising agency Antoni. In the future, Valneva, Novavax and Manganese X Energy want to contribute to the direct fight against the pandemic. Valneva and Novavax are in a neck-and-neck race for the first inactivated vaccine alternative to the top dogs BioNTech and Moderna. Newcomer Manganese wants to combat Corona with a new air disinfectant and has other arrows in its quiver.

Read

Commented by Carsten Mainitz on December 8th, 2021 | 12:53 CET

Pfizer, Defence Therapeutics, Novavax - Who will benefit from Omicron?

  • Biotechnology

The world is trembling before the new Corona variant Omicron. Stock exchanges are going down, panic reigns in the crypto markets and politicians are outbidding each other with calls for tighter lockdown regulations. However, some experienced epidemiologists already see the emergence of Omicron as an indication of an imminent change from pandemic to endemic, in which we will live with the Coronavirus as if it were the flu. However, everyone agrees on one thing: we will still need vaccination. Who is this good news for?

Read